CARMEL, Ind., Aug. 1, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, announced today that it will report financial results for the three months ended June 30, 2024, on Thursday, August 8, 2024, before the market opens. The Company has scheduled a conference call that same day, August 8, 2024, at 9:00 a.m. ET, to review the results.
Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at http://www.syrahealth.com/ir/presentations/q2-2024-earnings-call.
Investors who would like to submit a question to be addressed on the call should email the question to This email address is being protected from spambots. You need JavaScript enabled to view it..
A webcast replay will be available in the Investors section of the Company's website at http://www.syrahealth.com/ir/presentations/q2-2024-earnings-call.
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company powering better health in challenging areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology products. Syra Health's offerings are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.
Contact
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.50 |
Daily Change: | -0.24 -32.30 |
Daily Volume: | 37,618,596 |
Market Cap: | US$4.490M |
December 02, 2024 November 26, 2024 October 29, 2024 September 13, 2024 August 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load